Systemic adverse events at · adults with centre‐involving diabetic macular oedema
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid showed no clear difference in systemic adverse events at compared with intravitreal anti‐VEGF (low certainty).
1 finding from 1 review
Quality of life at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment probably leads to higher gain of 15 or more letters visual acuity at 1 year compared with control (moderate certainty).
1 finding from 1 review
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment leads to higher loss of fewer than 15 letters visual acuity at 1 year compared with control (high certainty).
1 finding from 1 review
Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration
1 finding from 1 review
Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vision‐related quality of life · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment probably leads to higher mean change in vision‐related quality of life compared with control (moderate certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · proliferative diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Visual acuity · proliferative diabetic retinopathy
1 finding from 1 review
Complete regression of new vessels (dichotomous outcome) · proliferative diabetic retinopathy
Anti‐vascular endothelial growth factor (anti‐VEGF) with or without… probably leads to higher complete regression of new vessels (dichotomous outcome) compared with PRP alone (moderate certainty).
1 finding from 1 review
Regression of new vessels (continuous outcome): mean area of fluorescein leakage (mm2) fluorescein angiography · proliferative diabetic retinopathy
1 finding from 1 review
Presence of vitreous haemorrhaged · proliferative diabetic retinopathy
Anti‐vascular endothelial growth factor (anti‐VEGF) with or without… probably leads to lower presence of vitreous haemorrhaged compared with PRP alone (moderate certainty).
1 finding from 1 review
Need for vitrectomy · proliferative diabetic retinopathy
Anti‐vascular endothelial growth factor (anti‐VEGF) with or without… may leads to lower need for vitrectomy compared with PRP alone (low certainty).
1 finding from 1 review
Quality of life (VFQ‐25 General health) · proliferative diabetic retinopathy
1 finding from 1 review
Adverse events · proliferative diabetic retinopathy
1 finding from 1 review
Number of anti‐VEGF injections · people with neovascular AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found